Goldman resumed coverage on Relay Therapeutics with a new price target

9/10/24 7:59:04 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Goldman resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $20.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RLAY

Date	Price Target	Rating	Analyst
4/17/2025	$4.00	Equal Weight	Wells Fargo
9/10/2024	$20.00	Buy	Goldman
9/10/2024		Outperform → Perform	Oppenheimer
9/10/2024	$10.60 → $16.00	Hold → Buy	Jefferies
5/10/2024	$15.00	Equal Weight → Overweight	Barclays
4/20/2023	$12.50	Underperform → Hold	Jefferies
4/19/2023	$29.00	Outperform → Strong Buy	Raymond James
4/13/2023	$29.00	Outperform	Raymond James